Sign In
Buy BIAF
$1.69
+0.0100 (+0.595%)
At Close: Jun 03, 2026
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
08:00am, Friday, 13'th Mar 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
12:55pm, Thursday, 05'th Mar 2026
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead?
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AAAAI--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BAMC--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 13.8% – Here’s What Happened
02:59am, Tuesday, 24'th Feb 2026
Shares of bioAffinity Technologies, Inc. (NASDAQ: BIAF - Get Free Report) dropped 13.8% during mid-day trading on Monday. The stock traded as low as $0.90 and last traded at $0.9305. Approximately 215
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study
08:00am, Tuesday, 17'th Feb 2026
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board.
bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
08:00am, Wednesday, 07'th Jan 2026
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity's laboratory, Precision Pathology Laboratory Services, maintains accreditation from the College of American Pathologists.
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 43.3% in December
04:20am, Saturday, 27'th Dec 2025
bioAffinity Technologies, Inc. (NASDAQ: BIAF - Get Free Report) saw a large drop in short interest in December. As of December 15th, there was short interest totaling 31,376 shares, a drop of 43.3% fr
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 4.9% – Here’s What Happened
02:27am, Saturday, 27'th Dec 2025
bioAffinity Technologies, Inc. (NASDAQ: BIAF - Get Free Report)'s stock price traded down 4.9% on Friday. The stock traded as low as $1.13 and last traded at $1.17. 115,248 shares were traded during m
Reviewing bioAffinity Technologies (NASDAQ:BIAF) and Briacell Therap (NASDAQ:BCTX)
02:14am, Sunday, 07'th Dec 2025
Briacell Therap (NASDAQ: BCTX - Get Free Report) and bioAffinity Technologies (NASDAQ: BIAF - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the
bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
08:00am, Wednesday, 03'rd Dec 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients.
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
12:35pm, Wednesday, 19'th Nov 2025
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
